You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》傳上海岸邁生物明年來港上市籌3億美元 鄭志剛、未來資產基金等為股東
阿思達克 09-08 15:09
據《路透》旗下IFR引述消息指,內地生物技術企業上海岸邁生物(EpimAb Bio)計劃最快明年在香港上市,集資額達3億美元。 官網資料顯示,岸邁生物在上海和蘇州分別設有研發中心和GMP生產基地,專注於利用自主知識產權的雙特異性抗體技術平台FIT-Ig,進行創新生物產品的研究和開發,目前正在針對免疫腫瘤和其他臨床需求高的領域進行雙特異性抗體系列原創產品的開發。 岸邁生物今年3月完成1.2億美元C輪融資,由招銀國際和韓國未來資產基金共同領投,弘毅投資、魚鷹資管、燕創資本、Octagon Capital、鄭志剛、上灣資本等共同參與,現有股東德誠資本、國投創新、夏爾巴投資及潛龍投資亦跟投,所得資金計劃用於推進岸邁生物的EMB-01,EMB-02和EMB-06正在進行的人體臨床研究,並拓展新型雙特異性抗體等生物藥的產品管線。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account